Confirmatory Study for AD-810N in Patients with Parkinsonism in Dementia with Lewy Bodies.(Phase 3 study)
Latest Information Update: 12 Apr 2022
At a glance
- Drugs Zonisamide (Primary)
- Indications Lewy body disease; Parkinson's disease
- Focus Registrational; Therapeutic Use
- Sponsors Sumitomo Dainippon Pharma
- 01 Mar 2022 Results(n=335)evaluating the long-term efficacy and safety of zonisamide in dementia with Lewy bodies, published in the American Journal of Geriatric Psychiatry
- 26 Feb 2018 Status changed from active, no longer recruiting to completed.
- 06 Apr 2017 According to a Sumitomo Dainippon Pharma media release, an extension study is ongoing.